Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Impax Pharmaceuticals has completed patient enrollment for its Phase III comparative study of IPX066 to carbidopa-levodopa and entacapone (CLE) involving patients with advanced Parkinson's disease (PD).
Subscribe to our email newsletter
An investigational extended release capsule formulation of carbidopa-levodopa (CD-LD)- IPX066, is aimed to treat motor symptoms of the PD.
The randomised, double-blind 2-treatment, 2-period crossover Ascend-PD study enrolled 110 subjects, of which 90 subjects enter the randomized comparative phase, following which the subjects will be enrolled in a six-month open-label extension phase.
The study results are expected in late August, 2011 while the company plans to file a New Drug Application for IPX066 in PD in the fourth quarter of 2011.
Impax earlier completed two pivotal phase III trials in advanced PD subjects and in early PD patients.
The drug is jointly developed by Impax and GlaxoSmithKline.